Hengrui Medicine: Paricalcitol injection passed the consistency evaluation of generic drugs

On May 25, Hengrui Medicine stated that it had recently received the "Drug Supplementary Application Approval Notice" for Paricalcitol injection approved and issued by the National Medical Products Administration.

Paricalcitol is a synthetic vitamin D analogue with biological activity, modified on the side chain (D2) and A ring (19-nor) of calcitriol.

Upon inquiry, the global sales of Paricalcitol-related dosage forms in 2020 will be approximately US$119 million.

According to relevant national policies and regulations, appropriate support should be given to medical insurance payment for drug varieties that have passed the consistency evaluation of generic drugs, and medical institutions should give priority to procurement and give priority to selection in clinical practice.

According to the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Drug Centralized and Volume Procurement" (Guobanfa [2021] No.